Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MEDX Stock Forecast 2026-2027
$34.99
Current Price
$0
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MEDX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MEDX Price Momentum
-3.8%
1 Week Change
+2.3%
1 Month Change
+25.6%
1 Year Change
+5.4%
Year-to-Date Change
-7.4%
From 52W High of $37.79
+29.2%
From 52W Low of $27.08
📊 TOP ANALYST CALLS
Did MEDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Horizon Kinetics ETF is one of their latest high-conviction picks.
Latest MEDX Stock Price Targets & Analyst Predictions
MEDX has shown a year-to-date change of 5.4% and a 1-year change of 25.6%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MEDX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MEDX Analyst Ratings
0
Buy
0
Hold
0
Sell
MEDX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $34.99
Latest MEDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MEDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 22, 2022 | Truist Securities | Hold | Maintains | $N/A | |
| Nov 23, 2021 | HSBC | Hold | Initiates | $N/A | |
| Nov 17, 2021 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Nov 11, 2021 | Jefferies | Hold | Upgrade | $N/A | |
| May 21, 2020 | SunTrust Robinson Humphrey | Buy | Maintains | $N/A | |
| May 11, 2020 | SunTrust Robinson Humphrey | Buy | Maintains | $N/A | |
| Apr 13, 2020 | SunTrust Robinson Humphrey | Buy | Maintains | $N/A | |
| Feb 21, 2020 | CFRA | Buy | Upgrade | $N/A | |
| Jan 21, 2020 | Jefferies | Buy | Upgrade | $N/A | |
| Oct 23, 2019 | Redburn | Neutral | Downgrade | $N/A | |
| Aug 1, 2019 | BTIG | Neutral | Downgrade | $N/A | |
| Jun 20, 2019 | Barclays | Overweight | Upgrade | $N/A | |
| Oct 26, 2018 | UBS | Buy | Upgrade | $N/A | |
| Oct 18, 2018 | DZ Bank | Hold | Downgrade | $N/A | |
| Aug 28, 2018 | HSBC | Buy | Upgrade | $N/A | |
| Apr 24, 2018 | Deutsche Bank | Buy | Upgrade | $N/A | |
| Mar 17, 2016 | Nomura | Buy | Initiates | $N/A | |
| Jan 5, 2016 | UBS | Buy | Upgrade | $N/A | |
| Oct 30, 2015 | PiperJaffray | Neutral | Maintains | $N/A | |
| Oct 30, 2015 | SunTrust Robinson Humphrey | Buy | Maintains | $N/A |
Horizon Kinetics Medical ETF (MEDX) Competitors
The following stocks are similar to Horizon Kinetics ETF based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MEDX
Horizon Kinetics
mkt cap
16.75B
Horizon Kinetics Medical ETF (MEDX) Financial Data
Horizon Kinetics Medical ETF has a market capitalization of $0 with a P/E ratio of 29.0x. The company generates $17.62B in trailing twelve-month revenue with a 28.8% profit margin.
Revenue growth is +7.1% quarter-over-quarter, while maintaining an operating margin of +10.9% and return on equity of +9.9%.
Valuation Metrics
Market Cap
$0
Enterprise Value
$11.84B
P/E Ratio
29.0x
PEG Ratio
N/A
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
+7.1%
Gross Margin
+26.7%
Operating Margin
+10.9%
Net Margin
+28.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
3.7x
Debt/Equity
1.2x
ROE
+9.9%
ROA
+2.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Horizon Kinetics Medical ETF (MEDX) Business Model
About Horizon Kinetics Medical ETF
What They Do
Provides exposure to the healthcare sector.
Business Model
This ETF generates revenue by pooling investor funds to invest in a diversified portfolio of healthcare-related companies, including those in biotechnology, pharmaceuticals, and medical devices. It aims to capitalize on the growth of innovative companies within the medical industry, allowing investors to benefit from advancements in healthcare without needing to select individual stocks.
Additional Information
Managed by Horizon Kinetics, the ETF focuses on companies that are significant in medical research and technology. It offers investors a way to participate in the important advancements in healthcare while addressing critical public health challenges.
Horizon Kinetics Medical ETF (MEDX) Latest News & Analysis
Latest News
Medical ETF (MEDX) Touches New 52-Week High
4 months ago
Quick Summary
MEDX has reached a new 52-week high, driven by strong performance in its patented pharmaceutical segment.
Why It Matters
MEDX's new 52-week high indicates strong market confidence and potential growth, driven by its patented drugs, which could attract more investors and boost stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Eli Lilly raised its 2024 outlook due to strong sales growth of its obesity drug Zepbound and diabetes drug Mounjaro.
Why It Matters
Eli Lilly's raised outlook indicates strong revenue growth potential, driven by Zepbound and Mounjaro sales, which may enhance stock performance and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Eli Lilly (LLY) reported strong Q4 2023 earnings, surpassing estimates due to high sales of diabetes and weight-loss treatments.
Why It Matters
Eli Lilly's strong Q4 2023 earnings, surpassing expectations, indicate robust demand for its diabetes and weight-loss drugs, boosting investor confidence and potential stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
2 years ago
Quick Summary
Eli Lilly (LLY) reported strong Q3 2023 earnings, surpassing estimates for revenue and profit. The Mounjaro anti-obesity drug showed continued strong performance.
Why It Matters
Eli Lilly's strong Q3 earnings and successful Mounjaro performance signal growth potential, positively influencing investor sentiment and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Eli Lilly (LLY) saw its stock surge significantly after a strong Q2 2023 earnings report and positive outlook, making ETFs with exposure to the company attractive investment options.
Why It Matters
Eli Lilly's stock surge signals strong financial health and growth potential, making ETFs with significant exposure attractive for capitalizing on this momentum.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Eli Lilly (LLY) will acquire DICE Therapeutics (DICE) for about $2.4 billion to enhance its immunology pipeline focused on immune disease treatments.
Why It Matters
Eli Lilly's acquisition of DICE Therapeutics enhances its immunology portfolio, potentially increasing future revenue and market competitiveness in immune disease treatments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About MEDX Stock
What is Horizon Kinetics Medical ETF's (MEDX) stock forecast for 2027?
Analyst forecasts for Horizon Kinetics Medical ETF (MEDX) are not currently available. The stock is trading at $34.99.
Is MEDX stock a good investment in 2027?
Analyst ratings for MEDX are not currently available. The stock is currently trading at $34.99. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MEDX stock?
Price predictions from Wall Street analysts for MEDX are not currently available. The stock is trading at $34.99.
What is Horizon Kinetics Medical ETF's business model?
This ETF generates revenue by pooling investor funds to invest in a diversified portfolio of healthcare-related companies, including those in biotechnology, pharmaceuticals, and medical devices. It aims to capitalize on the growth of innovative companies within the medical industry, allowing investors to benefit from advancements in healthcare without needing to select individual stocks.
What is the highest forecasted price for MEDX Horizon Kinetics Medical ETF?
Price targets from Wall Street analysts for MEDX are not currently available. The stock is trading at $34.99.
What is the lowest forecasted price for MEDX Horizon Kinetics Medical ETF?
Price targets from Wall Street analysts for MEDX are not currently available. The stock is trading at $34.99.
What is the overall MEDX consensus from analysts for Horizon Kinetics Medical ETF?
Analyst ratings for MEDX are not currently available. The stock is trading at $34.99.
How accurate are MEDX stock price projections?
Stock price projections, including those for Horizon Kinetics Medical ETF, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:45 AM UTC